Fig. 8 | Scientific Reports

Fig. 8

From: Mechanisms of rifaximin inhibition of hepatic fibrosis in mice with metabolic dysfunction associated steatohepatitis through the TLR4/NFκB pathway

Fig. 8

Rifaximin ameliorates MASH through the TLR4/NF-κB signaling pathway. Panel (A), effect of LPS on TLR4 expression rate. Panel (B), effect of TAK-242 on TLR4 expression rate detected by flow cytometry. Panel (C), the mRNA expression levels of IL-6. Panel (D), the mRNA expression levels of IL-1β. Panel (E), the mRNA expression levels of α-SMA. Panel (F), the mRNA expression levels of TGF-β. Panel (G), the mRNA expression levels of TLR4. Panel (H), the mRNA expression levels of NF-κB. *P < 0.05, **P < 0.01, ***P<0.001, ****P < 0.0001 compared with the C group. #P < 0.05, ##P < 0.01, ###P<0.001, ####P<0.0001 compared with the F group.

Back to article page